# Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

> **NCT06491472** · PHASE2 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 36 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT06491472
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2026-07-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491472, "Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06491472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*